Primäre medikamentöse Thromboembolieprophylaxe bei ambulanten Patienten mit fortgeschrittenem Pankreaskarzinom unter Chemotherapie?
Standard
Primäre medikamentöse Thromboembolieprophylaxe bei ambulanten Patienten mit fortgeschrittenem Pankreaskarzinom unter Chemotherapie? / Pelzer, U; Sinn, M; Stieler, J; Riess, H.
In: DEUT MED WOCHENSCHR, Vol. 138, No. 41, 10.2013, p. 2084-8.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Primäre medikamentöse Thromboembolieprophylaxe bei ambulanten Patienten mit fortgeschrittenem Pankreaskarzinom unter Chemotherapie?
AU - Pelzer, U
AU - Sinn, M
AU - Stieler, J
AU - Riess, H
N1 - © Georg Thieme Verlag KG Stuttgart · New York.
PY - 2013/10
Y1 - 2013/10
N2 - BACKGROUND AND OBJECTIVE: The indication for medical venous thrombosis prophylaxis in ambulatory cancer patients is still under discussion. To provide more data on this topic we conducted an analysis in ambulatory patients with advanced pancreatic adenocarcinoma, reflecting a patient cohort at high risk of symptomatic venous thromboembolism (sVTE).PATIENTS AND METHODS: Data from 312 consecutively recruited patients of the CONKO-004 trial were analysed according to predefined parameters and additionally with respect to established scores. To focus on patients with highest risk of sVTE unvaried and multivariate analyses were conducted.RESULTS: The global analyses had educed a number needed to treat (NNT) by medical thrombosis prophylaxis of 12 patients to prevent one sVTE. The modified score model did not provide further clinical benefit. However, the regression model can identify single parameters with a trend to higher risk of sVTE or higher risk of severe bleeding. Most of the parameters do not have enough power to be significant, but they can support clinical decisions.CONCLUSION: These data suggest that medical thrombosis prophylaxis should be performed in patients with advanced pancreatic cancer at least for the initial 3 months of first line chemotherapy.
AB - BACKGROUND AND OBJECTIVE: The indication for medical venous thrombosis prophylaxis in ambulatory cancer patients is still under discussion. To provide more data on this topic we conducted an analysis in ambulatory patients with advanced pancreatic adenocarcinoma, reflecting a patient cohort at high risk of symptomatic venous thromboembolism (sVTE).PATIENTS AND METHODS: Data from 312 consecutively recruited patients of the CONKO-004 trial were analysed according to predefined parameters and additionally with respect to established scores. To focus on patients with highest risk of sVTE unvaried and multivariate analyses were conducted.RESULTS: The global analyses had educed a number needed to treat (NNT) by medical thrombosis prophylaxis of 12 patients to prevent one sVTE. The modified score model did not provide further clinical benefit. However, the regression model can identify single parameters with a trend to higher risk of sVTE or higher risk of severe bleeding. Most of the parameters do not have enough power to be significant, but they can support clinical decisions.CONCLUSION: These data suggest that medical thrombosis prophylaxis should be performed in patients with advanced pancreatic cancer at least for the initial 3 months of first line chemotherapy.
KW - Adenocarcinoma/blood
KW - Ambulatory Care
KW - Anticoagulants/administration & dosage
KW - Dalteparin/administration & dosage
KW - Dose-Response Relationship, Drug
KW - Enoxaparin/administration & dosage
KW - Hemorrhage/blood
KW - Humans
KW - Injections, Subcutaneous
KW - Pancreatic Neoplasms/blood
KW - Prospective Studies
KW - Randomized Controlled Trials as Topic
KW - Risk Factors
KW - Survival Rate
KW - Venous Thromboembolism/mortality
U2 - 10.1055/s-0033-1349608
DO - 10.1055/s-0033-1349608
M3 - SCORING: Zeitschriftenaufsatz
C2 - 24085361
VL - 138
SP - 2084
EP - 2088
JO - DEUT MED WOCHENSCHR
JF - DEUT MED WOCHENSCHR
SN - 0012-0472
IS - 41
ER -